Recherche
-
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)
(Trials. vol. 21, n° 1, pp. 846, 2020-10-13)Article de revueLibre accès -
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).
(Clinical Microbiology and Infection. vol. 28, n° 7, pp. 1010-1016, 2022-07-01)Article de revueLibre accès -
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
(The Lancet Infectious Diseases, 2020-11-17)Article de revue -
Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
(Frontiers in Immunology. vol. 10, 2019-04-24)Article de revueLibre accès -
ChatGPT and beyond with artificial intelligence (AI) in health: Lessons to be learned.
(Joint Bone Spine. vol. 90, n° 5, pp. 105607, 2023-09-01)Article de revue -
Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
(International Journal of Infectious Diseases. vol. 74, pp. 83-96, 2018-09)Article de revueLibre accès -
A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1 infected individuals: VRI02 ANRS 149 LIGHT Phase II trial
(Journal of Virology, 2021-02-10)Article de revueLibre accès -
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
(Journal of Immunology. vol. 208, n° 12, pp. 2663-2674, 2022-06-15)Article de revue